Calypso Biotech is a biopharmaceutical company specializing in the development of therapeutic antibodies against severe (auto)immune diseases. Calypso’s lead program, CALY-002, is a best in class antibody which binds to and neutralizes interleukin-15 (IL-15), an immune checkpoint with an role in severe pathologies. CALY-002 is being developed for Eosinophilic Esophagitis (EoE), an emerging immune pathology driven by food antigens and resulting in severe dysphagia and poor quality of life in children and adults. With more than 300 000 people living with EoE, and no approved biologicals on the market today, a large unmet need for effective treatment exists. CALY-002 has obtained orphan drug designation.

Calypso raised €20M in financing led by Gilde Healthcare to bring CALY-002 into the clinic for EoE and other indications.